DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bivatuzumab mertansine
Bivatuzumab mertansine
The Evolving Concept of Cancer and Metastasis Stem Cells
Molecular Interactions of Erbb Receptor Tyrosine Kinases and Integrin Β1: Implications for Tumor Therapy
University of Groningen PET Imaging and in Silico Analyses to Support
Review Article Cd44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches
Ep 3178848 A1
Ep 3321281 A1
Archivio Istituzionale Open Access Dell'università Di Torino Original
(12) Patent Application Publication (10) Pub. No.: US 2016/0166697 A1 Bender (43) Pub
Investigating the Roles of CD44 and CD147 in Prostate Cancer Metastasis and Drug-Resistance
Immunogen, Inc. Regains Development and Commercialization Rights for Cantuzumab Mertansine
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies
WO 2019/028191 Al 07 February 2019 (07.02.2019) W !P O PCT
Conditions of Tumor-Associated Antigens As a Proper Target for Therapeutic Antibodies Against Solid Cancers
Antibody Drug Conjugates (ADC)
WO 2018/183580 Al 04 October 2018 (04.10.2018) W !P O PCT
Wo 2010/095940 A2
Top View
Potential Mechanisms of Target-Independent Uptake and Toxicity of Antibody-Drug Conjugates
Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: a Systematic Review
The Power to Deliver Letter to Our Shareholders Immunogen, Inc
VU Research Portal
A Phase I Dose Escalation Study with Anti-Cd44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck Or Esophagus Bernard M
Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: the Rationale for Combination Therapies
Immunogen, Inc. Announces Publication of Cantuzumab Mertansine Phase I Study in the Journal of Clinical Oncology
The Tumor Targeting Performance of Anti-CD166 Probody Drug Conjugate CX
(12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
Patient Selection Strategies to Maximize Therapeutic Index Of
International Journal of Current Advanced Research
Pharmacokinetics, Immunogenicity and Safety of Bivatuzumab
Development of Novel Qspr Strategy and Models for the Solubility Prediction and In-Silico Bioavailability Study of Paclitaxel Prodrugs
1770.Full-Text.Pdf
New Developments for Antibody-Drug Conjugate-Based Therapeutic
Immunogen, Inc. Announces Start of Phase II Study with Hun901-DM1 in Patients with Relapsed Small-Cell Lung Cancer
Dihydropyrrolidino-Pyrimidines As Kinase Inhibitors Dihydropyrrolidinpyrimidine Als Kinaseinhibitoren Dihydropyrrolidinopyrimidines Comme Inhibiteurs De Kinase
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al